Drug Profile
Research programme: targeted cancer diagnostics - Cancer Targeted Technology/GE Healthcare
Latest Information Update: 20 Dec 2010
Price :
$50
*
At a glance
- Originator CTT Cancer Targeting Technologies; GE Healthcare
- Class Cyclic peptides; Diagnostic agents
- Mechanism of Action Gelatinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Dec 2010 Discontinued - Preclinical for Cancer in Finland (unspecified route)
- 10 Nov 2006 Preclinical trials in Diagnostic imaging in Finland (unspecified route)